Abstract

Objective: To study the metformin in human oral squamous cell carcinomas SCC-4 and CAL-27 cell inhibitory effect and its molecular mechanism.

Methods: With human oral squamous cell carcinomas Squamous Cell Carcinoma-4 (SCC-4) and CAL-27 subcutaneous transplantation tumor cells and nude mouse models as the research subjects, we carried out MTT assay, flow cytometry assay and Western blot assay methods, so as to investigate the effects of metformin on cell proliferation, activity, clone formation and cycle in in-vitro culture of human oral squamous cell carcinomas SCC-4 and CAL-27 cells, and to explore its molecular mechanism.

Results: The activity of oral squamous cell carcinomas SCC-4 and CAL-27 cells in different concentration intervention after 48 h activity were reduced (p<0.05) in comparison with the control group, and presented an obvious concentration-dependent manner. By treatment of metformin in different concentration for two weeks, compared with the normal control group, oral squamous cell carcinomas SCC-4 and CAL-27 cell clone number were significantly reduced (p<0.05), and the reduction was in an obvious concentration-dependent manner.

Conclusion: Metformin can reduce the activity of oral squamous cell carcinomas SCC-4 and CAL-27 cell, inhibit the proliferation and clone formation of oral squamous cancer cell, and the oral squamous cell carcinomas SCC-4 and CAL-27 cell growth is stopped in G0/G1 phase, thereby activating AMPK signaling pathways and inhibiting mTOR signaling pathways.

Keywords: Metformin, Oral squamous cell carcinomas, SCC-4 cells, CAL-27 cells, Molecular mechanisms.
diphenyltetrazolium bromide), paraformaldehyde, crystal violet, etc.

**Experiment methods**

Various experimental solutions were prepared for the resuscitation, culture and passage of oral squamous cell carcinoma SCC-4 cell strain and CAL-27 cell strain, including the RPMI-1640 culture medium, Dulbecco’s Modified Eagle Medium (DMEM), Phosphate Buffer Saline (PBS), 0.25% trypsin, and 0.02% Ethylene Diamine Tetraacetic Acid (EDTA). Then we applied the MTT, cytometry, and Western-blot methods to investigate the effects of metformin on in-vitro proliferation capability, cell activity, clone formation and cell cycle of human oral squamous cell carcinoma SCC-4 cell and CAL-27 cell and clarify the relevant molecular mechanism.

(1) Detecting the in-vitro proliferation capability of cells via MTT method: Human oral squamous cell carcinoma SCC-4 cell and CAL-27 cell in the logarithmic phase were taken for regular digestion, centrifugation and resuspension to prepare the single cell suspension. Cells were inoculated onto the 96-well plate in 5 × 10^3/well. Plate was then transferred into an incubator for over 24 h of cell culture at 37°C in 5% CO2. Then the original medium in each well was removed and media with 2, 5, 10 and 20 mM metformin were added. After 2 w of regular culture, 20 μL MTT (5 mg/ml) was added onto each well followed by over 4 h of regular culture. The supernatant was discarded, and the Optical Density (PD) at 490 nm wavelength of each well was detected. The survival rate of cell was calculated using the following formula: survival rate=OD value of experiment group/OD value of control group ×100%.

(2) Detecting the clone formation of cells: Human oral squamous cell carcinoma SCC-4 cell and CAL-27 cell in the logarithmic phase were taken for regular digestion, centrifugation and resuspension to prepare the single cell suspension. Cells were inoculated onto the 6-well plate in 1 × 10^5/well. Plate was then transferred into an incubator for over 24 h of cell culture at 37°C in 5% CO2. Then the original medium in each well was removed, media containing 5% FBS and media with 2, 5, and 10 mM metformin were added. After 2 w of regular culture, the original media were removed and the plate was washed for 3 times using PBS, fixed using 4% paraformaldehyde, and then washed by PBS for 3 times After 5 min of staining using 0.1% crystal violet, the plate was carefully rinsed using deionized water until the solution turned into colorless and clear. Finally, we applied the high power digital camera to record the results, and analysis of clone formation of cells was carried out using Quantity One software. The rate of cell clone formation was calculated using the following formula: Formation rate of cell clone=Quantity of clone in experiment group/Quantity of clone in control group ×100%.

(3) Detecting the cell cycle via flow cytometry: Human oral squamous cell carcinoma SCC-4 cell and CAL-27 cell in the logarithmic phase were taken for regular digestion, centrifugation and resuspension to prepare the single cell suspension. Cells were inoculated onto the 6-well plate in 2 × 10^5/well. Plate was then transferred into an incubator for over 24 h of cell culture at 37°C in 5% CO2. Then the original medium in each well was removed and media containing 5 mM metformin were added. After 12, 24 and 48 h of regular culture, cells were digested using trypsin followed by the centrifugation and collection of cells. Then cells were washed using PBS, and the ratio of cells in each cycle was analysed using flow cytometer and Modifit software. Then the original medium in each well was removed and media containing 5 mM metformin were added. After 20 μL MTT (5 mg/ml) was added onto the membrane according to the species origin for 1 h of incubation. ECL developer was prepared. After the buffer saline+Tween 20 (TBST) on the NC membrane was removed, 5 ml ECL developer was added onto the membrane followed by blow, beat and well-mixing. Then the ECL developer on the membrane was removed, and the membrane was then placed into a dark room equipped with Bio-Rad apparatus. The time of exposure was adjusted according to the brightness of stripes, and the pictures were collected using Image Lab software.

**Statistical methods**

Statistical analysis of data was then carried out using the SPSS 19.0 software. Measurement data were presented as mean ± standard deviation. Chi-square test was performed in comparison of count data. In this study, p<0.05 suggested that the difference had statistical significance.

**Results**

**Inhibitory effect of metformin on the in-vitro proliferation capability of oral squamous cell carcinoma SCC-4 cell and CAL-27 cell**

In this study, MTT detection was applied to detect the effects of metformin on oral squamous cell carcinoma SCC-4 cell and CAL-27 cell. According to Figure 1, we found that at 48 h after the intervention of metformin in different concentrations on oral squamous cell carcinoma SCC-4 cells, cell activities, when compared with the control group (p<0.05), were reduced by (19.51 ± 2.93%), (44.48 ± 7.85%), (54.83 ± 5.63%) and (63.94 ± 4.46%), respectively (Figure 1A); at 48 h after the intervention of metformin in different concentrations on oral squamous cell carcinoma CAL-27 cells, cell activities, when compared with the control group (p<0.05), were reduced by (10.48 ± 3.08%), (20.74 ± 2.73%), (38.25 ± 4.65%) and (47.49 ± 6.08%), respectively (Figure 1B). This indicated that
metformin can significantly reduce the activity of oral squamous cell carcinoma SCC-4 cell and CAL-27 cell, inhibit the cell proliferation in oral squamous cell carcinoma, and the inhibitory pattern shows an obvious reliance on the concentration of metformin.

**Figure 1.** Effects of the different concentrations of metformin on the activity of SCC-4/CAL-27 cells in oral squamous cell carcinoma after 48 h. *Compared with the control group; p<0.05.

### Blocking effect of metformin on the cell cycle of oral squamous cell carcinoma SCC-4 cell and CAL-27 cell

In this study, flow cytometry was performed for analyzing the blocking effect of metformin on the cell cycle of oral squamous cell carcinoma SCC-4 cell and CAL-27 cell. As shown in Figures 2 and 3, at 12 h, 24 h and 48 h after the intervention of 5 mM metformin for oral squamous cell carcinoma SCC-4 cell and CAL-27 cell, gradual increases were identified in the ratio of cells in G$_0$/G$_1$ phase over time, significantly higher than those in the control group at the same time point (p<0.05), but a gradual decrease was also seen in the ratio of cells in S and G$_2$/M phases. This indicated that metformin can block the growth of oral squamous cell carcinoma SCC-4 cell and CAL-27 cell in G$_0$/G$_1$ phase.

**Figure 2.** Effects of 5 mM metformin on cell cycle of SCC-4 and CAL-27 cells in oral squamous cell carcinoma.

### Inhibitory effect of metformin on the clone formation of oral squamous cell carcinoma SCC-4 cell and CAL-7 cell

Figure 4A is the high-power microscopic images of cells in 6-well plate that were treated using 2 Mm, 5mM and 10 mM of metformin. From the Figure 4A, after 2 w of intervention using metformin in different concentrations, the quantity of clones was significantly decreased when compared with those in the control group. Even if the concentration of metformin was only 2 mM, the count of clone formations of the oral squamous cell carcinoma SCC-4 cell and CAL-27 cell was also significantly decreased by (54.83 ± 10.46%) and (42.42 ± 11.28%) in comparison with that in the control group, and the difference had statistical significance (p<0.05). Additionally, with an increase in the concentration of metformin, a gradual decrease was found in the count of clone formation of oral squamous cell carcinoma SCC-4 cell and CAL-27 cell in an obvious concentration-dependent manner (Figure 4B). All these results showed that metformin can significantly suppress the clone formation of oral squamous cell carcinoma SCC-4 cell and CAL-27 cell.

**Figure 3.** The growth cycle distribution of SCC-4/CAL-27 cells in oral squamous cell carcinoma after the intervention of 5mM metformin. *Compared with the control group, p<0.05.

**Figure 4.** The inhibitory effect of metformin on cloning and progression of SCC-4 and CAL-27 Cells. A: SCC-4 and CAL-27 cells in metformin concentration of 2 mM, 5 mM, 10 Mm of 6 orifice plate culture media at high magnification microscope photograph figure; B: Cloning and progression of SCC-4 and CAL-27 cells in oral squamous cell. *Compared with the control group: p<0.05.
Effect of metformin on the AMPK/mTOR signal pathway of oral squamous cell carcinoma SCC-4 cell and CAL-27 cell

In this study, we extracted the total protein of oral squamous cell carcinoma SCC-4 cell and CAL-27 cell that were intervened using metformin in concentration of 5 mM in different time points (0 h, 24 h, 48 h and 72 h). With β-actin as the reference protein, we applied the Western-blot method to detect the expressions of AMPK/mTOR signal pathway, and the results were shown in Figure 5. From the Figure 5A, we found that after the intervention of metformin in concentration of 5 mM on the oral squamous cell carcinoma SCC-4 cell and CAL-27 cell, significant changes were observed in the total quantity of AMPKa, and significant increases were also identified in phosphorylation level of AMPKa (Thr172) in a significant time-dependent manner. This indicated that metformin can activate the AMPK signal pathway in oral squamous cell carcinoma SCC-4 cell and CAL-27 cell. From Figure 5B, we could see that after the intervention of metformin in concentration of 5 mM on the oral squamous cell carcinoma SCC-4 cell and CAL-27 cell, obvious decreases were observed in the expressions of mTOR and the downstream target molecules, such as p-mTOR (Ser2448), p-S6K1 (Thr389) and p-4E-BP1 (Thr37/46) in a significant time-dependent manner. This suggested that metformin can inhibit the mTOR signal pathway in oral squamous cell carcinoma SCC-4 cell and CAL-27 cell. These results showed that metformin can inhibit the proliferation and growth of oral squamous cell carcinoma SCC-4 cell and CAL-27 cell through activating the AMPK signal pathway.

![Figure 5](image)

**Figure 5.** Effects of metformin on AMPK and mTOR signaling pathway in oral squamous cell carcinoma SCC-4 cell and CAL-27 cells.

Discussion

Metformin is a kind of antidiabetic agent that has been widely applied in clinical practice, and is characterized by various advantages, such as the rapid decrease in the blood glucose, exact efficacy and few side reactions. Additionally, the research showed that metformin has a significant inhibitory effect on multiple tumor cells [4]. In this study, oral squamous cell carcinoma SCC-4 cell and CAL-27 cell were selected as the subjects, and the study showed that: At 48 h after the intervention of metformin in different concentrations on oral squamous cell carcinoma SCC-4 cells, cell activities, when compared with the control group (p<0.05), were reduced in an obvious concentration-dependent manner; after 2 w of intervention using metformin in different concentrations, the quantity of clones was significantly decreased when compared with those in the control group (p<0.05) in an obvious concentration-dependent manner; at 12 h, 24 h and 48 h after the intervention of 5 mM metformin for oral squamous cell carcinoma SCC-4 cell and CAL-27 cell, gradual increases were identified in the ratio of cells in G0/G1 phase over time in a time-dependent manner. These results are coincident with the research results of the inhibitory effect of metformin on other tumor cells [5-7].

Cell proliferation in tumor depends on the smooth implementation of cell cycles. Generally, cell cycles in tumor sequentially consist of G0/G1, S, G2, and M [8]. If cell growth can be stagnated in the period from G0/G1 to S, an important rate-limiting period of cell cycle in tumors, cell mitosis would be inhibited [9]. Thus, inducing the stagnation of cell growth in tumors in G0/G1 has been considered as one of the important mechanisms in suppressing the cell proliferation in tumors, which has been confirmed in the various experimental studies on the tumor cells, such as prostatic cancer [1], breast cancer [2], and gastric cancer [3]. In this study, we found that at 12, 24 h and 48 h after the intervention of 5 mM metformin for oral squamous cell carcinoma SCC-4 cell and CAL-27 cell, gradual increases were identified in the ratio of cells in G0/G1 phase over time in a time-dependent manner. This indicated that metformin can affect the cell cycle of oral squamous cell carcinoma SCC-4 cell and CAL-27 cell to inhibit the cell proliferation.

Adenosine Monophosphate Activated Protein Kinase (AMPK), as a kind of “energy sensing enzyme” that exists in the eukaryotic cells in human, can participate in the energetic metabolism in the body [10]. AMPK will be activated when the ratio of AMP/ATP in cells is elevated under the lack of energy, which will further result in the activation of downstream signal pathway, thus affecting the stability of cells [11]. In this study, we found that after the intervention of metformin in concentration of 5 mM on the oral squamous cell carcinoma SCC-4 cell and CAL-27 cell, significant changes were observed in the total quantity of AMPKa, but significant increases were also identified in phosphorylation level of AMPKa (Thr72) in a significant time-dependent manner; obvious decreases were observed in the expressions of mTOR and the downstream target molecules, such as p-mTOR (Ser2448), p-S6K1 (Thr389) and p-4E-BP1 (Thr37/46) in a significant time-dependent manner. Metformin can significantly increase the phosphorylation level of AMPK on the locus of Thr72 in the oral squamous cell carcinoma SCC-4 cell and CAL-27 cell, indicating that the inhibitory effect on cell proliferation of oral squamous cell carcinoma might be realized through the activation of AMPK signal pathway, but further studies are expected to clarify whether the inhibitory
effect of metformin on the mTOR signal pathway in the cells of oral squamous cell carcinoma depends on the activation of AMPK signal pathway.

In conclusion, metformin can decrease the cell activity of oral squamous cell carcinoma SCC-4 cell and CAL-27 cell, inhibit the cell proliferation and clone formation in oral squamous cell carcinoma, and induce the stagnation of cell growth of oral squamous cell carcinoma in G0/G1. The mechanism of inhibition is correlated with the activation of AMPK signal pathway and the inhibition of mTOR signal pathway.

References

*Correspondence to
Xiang tao Weng
Guangzhou University of Chinese Medicine
PR China
Wenjing Zhang
Guangzhou University of Chinese Medicine
PR China